MA-VERACODE
14.2.2024 13:51:34 CET | Business Wire | Press release
Veracode, a global leader in intelligent software security, today unveils its annual State of Software Security (SoSS) 2024 report, shedding light on the pressing issue of security debt in applications. Security debt, defined for this report as flaws that remain unfixed for longer than a year, exists in 42 percent of applications and 71 percent of organizations. Worryingly, 46 percent of organizations have persistent, high-severity flaws that constitute ‘critical’ security debt, putting businesses at serious risk in terms of impact on confidentiality, integrity, and availability.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240214981363/en/
State of Software Security 2024 Figure 25: Effect of flaw remediation speed on prevalence of security debt (Graphic: Business Wire)
According to the report, approximately 63 percent of applications have flaws in first-party code, while 70 percent contain flaws in third-party code imported via third-party libraries. This highlights the importance of testing both types throughout the software development life cycle. Remediation rates also vary by flaw type—fixing third-party flaws takes 50 percent longer, with half the known flaws fixed after 11 months, compared to seven months for first-party flaws.
There is good news, however: high-severity security flaws in applications have decreased by half since 2016, indicating progress in software security practices and that speed of remediation has a material impact on critical security debt.
SoSS 2024 reveals development teams that fix flaws the fastest reduce critical security debt by 75 percent—from 22.4 percent of applications to just over five percent. Moreover, these fast-acting teams are four times less likely to let critical security debt materialize in their applications in the first place.
Chris Eng, Chief Research Officer at Veracode, said, "While we continue to see improvements in the security landscape, these findings are a wake-up call for organizations to address their security debt head-on. By prioritizing flaw remediation, focusing on third-party code security, and adopting efficient development practices, organizations can significantly reduce their security debt and enhance the overall state of software security across the board."
Addressing AI and the Software Supply Chain
In an era where AI (artificial intelligence) is rapidly revolutionizing software development, the report highlights a concerning trend. Chris said, “Despite the speed and efficiency AI brings to software development, it does not necessarily produce code that’s secure. Research has shown that 36 percent of code generated by GitHub CoPilot contains security flaws.” This proliferation of insecure code at scale poses a significant risk to organizations and the software supply chain, leading to the accumulation of security debt over time.
Risk Prioritization is Key
Veracode’s research also found remediation capacity among teams to be constrained, with only 64 percent of applications having a remediation capacity that’s sufficient to eliminate critical security debt. In fact, only two out of ten applications show an average monthly fix rate that exceeds ten percent of all security flaws. This suggests, even in cases where teams’ fix capacity is sufficient, they are not prioritizing critical flaws.
Despite this, there is hope for success. Only three percent of all flaws constitute critical security debt, and this subset represents the largest risk exposure for applications. By prioritizing that three percent, organizations can achieve maximum risk reduction with focused effort.
Chris closed, "AI also paves the way for a new frontier in software security by empowering organizations to scale remediation efforts and more easily address the long backlog of security debt, as well as new flaws that emerge. The vast majority of CWEs (Common Weakness Enumeration) with a severity rating from medium to very high can be addressed through AI-generated code edits from Veracode Fix.”
The full State of Software Security 2024 report is available to download on the Veracode website. To access the report and gain deeper insights into the findings and recommendations, visit the website. A blog outlining the key findings from the report is also available to read.
-END-
About the State of Software Security Report
The Veracode State of Software Security 2024 report analyzed data from large and small companies, commercial software suppliers, software outsourcers, and open-source projects. The research draws from more than a million (1,007,133) applications across all scan types, 1,553,022 dynamic analysis scans, and 11,429,365 static analysis scans. All those scans produced 96 million raw static findings, 4 million raw dynamic findings, and 12.2 million raw software composition analysis findings.
About Veracode
Veracode is intelligent software security. The Veracode Software Security Platform continuously finds flaws and vulnerabilities at every stage of the modern software development lifecycle. Using powerful AI trained on a carefully curated, trusted dataset from experience analyzing trillions of lines of code, Veracode customers fix flaws faster with high accuracy. Trusted by security teams, developers, and business leaders from thousands of the world’s leading organizations, Veracode is the pioneer, continuing to redefine what intelligent software security means.
Learn more at www.veracode.com, on the Veracode blog, and on LinkedIn and Twitter.
Copyright © 2024 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240214981363/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
